https://hotcopper.com.au/threads/ann-agreement-with-c14-consulting-group.8180478/Language of the Vectus ANN is a bit similar to BIT's one, but Vectus' ANN contains some
more details.Hoy, not Michelle, will update the market with more clear details. Michelle appears to have copied and pasted some contents from Vectus ANN.
Anyway, let's wait and see what unfold in 2025. My MSB has been showing spectacular price performance since Dec 2024. BIT holders would be delighted to see spectacular price performance in BIT's SP. Michelle and Hoy need to team with C14 to take Michelle's progress to the executed deal....in 2025. My MSB is now around $3.35/s, BIT's SHs would like to see BIT's SP at least $0.35/s. Best wishes!
"...
30 August 2024
Company Announcements Office
Australian Securities Exchange
Agreement with C14 Consulting Group
Consistent with the Company’s strategic initiatives on commercialisation, Vectus has appointed C14
Consulting Group, LLC in an exclusive role to lead and manage the programme of potential licencing, joint
venture or both of Vectus’ portfolio of patented small therapeutic molecules, including the human lead
VB0004.
Vectus’ drug library focuses on a range of anti-fibrotic applications aimed at cardio vascular disease, a
significant unmet need. Specifically, VB0004, A32, A79 target reversal of disease in the heart, lung, kidney
and liver. VB0004 has successfully undergone human Phase Ia trials and more recently Phase Ib human
trials, with no adverse events recorded.
Based in the USA, C14 is a highly regarded consultancy with a global capability. Led by Martina Molsbergen
(Chief Executive Officer),
the company has an enviable track record of securing licence agreements, joint
ventures and commercialisation of pharmaceutical patented assets with all levels of pharma from large
scale to biotech companies that specialise in orphan and targeted applications. C14 will now be managing
existing discussions with, and expanding the outreach to, potential pharmaceutical partners.
C14 has
demonstrated that it has long standing relationships with a broad cross section of pharmaceutical
companies and a detailed knowledge of the indications and market segments on which each of these
companies are currently focusing.Providing for a management fee and an outcome-based success component, the agreement aligns the
interests of the parties achieving one or more commercial outcomes. C14 business model is predicated on
a broad analysis of the client’s technologies and typically engages with a client when there is a belief in the
potential of the technology to be commercialised.
Ms Martina Molsbergen, Chief Executive Officer of the licencing firm in the USA, C14 Consulting Group
commented: “C14 has a long track record in helping companies such as Vectus to advance towards the
commercialisation of novel therapies. From our preliminary review of VB0004 and associated drug library,
we have realised the compelling research that has been conducted thus far and the potential to be taken
up by pharma in the exciting space of fibrosis remediation.”
Dr Ron Shnier, Vectus Non-Executive Chairman said: “We are pleased to be partnering with C14, one of the
world’s leading consultancies in pharmaceutical transactions. As previously reported, Vectus is
concentrating its activities on achieving licencing or partnerships with its patented anti-fibrotic portfolio.”
Vectus Biosystems Limited
Dr Ron Shnier
Chairman
"
(20min delay)